Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines

Abstract excerpt

The benefit of PARP inhibitor olaparib in relapsed and advanced high-grade serous ovarian carcinoma (HGSOC) is well established especially in BRCA1/2 mutation carriers. Identification of additional biomarkers can help expand the population of patients most likely to benefit from olaparib treatment. To identify candidate markers of olaparib response we analyzed genomic and in vitro olaparib response data from two...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Ovarian cancer diagnosis and treatment
• Share to PARP inhibition in cancer therapy